摘要
目的观察帕利哌酮治疗精神分裂症的疗效、不良反应及对血清催乳素水平的影响。方法将80例精神分裂症患者随机分为研究组(帕利哌酮组,40例)和对照组(阿立哌唑组,40例),观察8周。以阳性和阴性症状量表(PANSS)评估疗效,治疗时出现的症状量表(TESS)评估不良反应,同时于治疗前和治疗后第4、8周末检测两组的血清催乳素水平。结果至研究终点,两组PANSS总分及各因子分均较治疗前有明显下降(P(0.01);组间比较仅第2周末研究组PANSS总分及阳性症状分好于对照组(P<0.05)。两组有效率分别为67.5%、62.5%,疗效相似(P>0.05)。帕利哌酮组催乳素水平明显升高,阿立哌唑组则有降低,差异有统计学意义(P<0.01)。两组均未出现严重不良反应。结论帕利哌酮治疗精神分裂症安全、有效,与阿立哌唑相当,但能升高血清催乳素水平。
Objective To explore the clinical efficacy, adverse effects of paliperidone ER and its influence on serum prolactin in treatment of schizophrenia. Methods 80 patients with schizophrenia were randomly assigned to study group （paliperidone ER,n=40） and control group （aripiprazole,n=40）.The clinical efficacy was evaluated with the Positive and Negative Syndrome Scale （ PANSS）, side effects were done with the Treatment Emergent Symptom Scale （TESS） in an 8-week open-label study. The levels of serum prolactin were detected before treatment and at the end of week 4 and 8. Results At endpoint, there were significant differences in total score and subscores of PANSS （P﹤0.01） in two groups. There were differences in PANSS total score and positive syndrome score between groups just at the second week（P﹤0.05）. The efficacy rate of two groups were 67.5%,62.5% respectively , without statistically significant difference（P﹥0.05）. The serum prolatin levels were higher than those before treatment in study group （P﹤0.05）,while the serum prolatin levels were lower in control group（P﹥0.05. There were no severity adverse effects in two groups. Conclusions Paliperidone ER as well as aripiprazole appears to be a safe and effective for schizophrenia although it can elevate the serum prolactin.
出处
《齐齐哈尔医学院学报》
2011年第3期351-353,共3页
Journal of Qiqihar Medical University
